BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 1347423)

  • 1. C-erbB-2 protein and neuroendocrine expression in intraductal carcinomas of the breast.
    Lilleng R; Hagmar BM; Nesland JM
    Mod Pathol; 1992 Jan; 5(1):41-7. PubMed ID: 1347423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C-erbB-2 protein and neuroendocrine expression in breast carcinomas.
    Nesland JM; Ottestad L; Heikilla R; Holm R; Tveit K; Børresen AL
    Anticancer Res; 1991; 11(1):161-7. PubMed ID: 1673329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estrogen and progesterone receptor and c-erbB-2 oncoprotein analysis in pure in situ breast carcinoma: an immunohistochemical study.
    Wilbur DC; Barrows GH
    Mod Pathol; 1993 Mar; 6(2):114-20. PubMed ID: 8097877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Expression of the c-erbB-2 oncoprotein in mammary Paget's disease. Immunohistochemical study by using 3 antibodies].
    Edorh A; Parache RM; Migeon C; N'Sossani B; Rihn B
    Pathol Biol (Paris); 1995 Sep; 43(7):584-9. PubMed ID: 8570262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significance of immunohistochemically detected c-erbB-2 protein expression in stage III breast cancer, with reference to nuclear deformity, DNA content and prognosis.
    Tamura G; Maesawa C; Mikawa S; Satodate R
    Jpn J Clin Oncol; 1991 Aug; 21(4):264-7. PubMed ID: 1682519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of c-erb B-2 protein and DNA ploidy in breast carcinogenesis.
    Schmitt FC; Figueiredo P; Lacerda M
    Arch Pathol Lab Med; 1995 Sep; 119(9):815-20. PubMed ID: 7668939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurone specific enolase immunostaining in the diagnosis of breast carcinomas with neuroendocrine differentiation. Its usefulness and limitations.
    Nesland JM; Holm R; Johannessen JV; Gould VE
    J Pathol; 1986 Jan; 148(1):35-43. PubMed ID: 3003312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nuclear DNA content in breast carcinomas with neuroendocrine differentiation.
    Nesland JM; Pettersen EO; Fosså SD; Høie J; Johannessen JV
    J Pathol; 1986 Nov; 150(3):181-5. PubMed ID: 3027292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of p53 protein in infiltrating and in-situ breast carcinomas.
    Walker RA; Dearing SJ; Lane DP; Varley JM
    J Pathol; 1991 Nov; 165(3):203-11. PubMed ID: 1684809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and prognostic significance of the expression of the c-erbB-2 and c-erbB-3 oncoproteins in primary and metastatic malignant melanomas and breast carcinomas.
    Bodey B; Bodey B; Gröger AM; Luck JV; Siegel SE; Taylor CR; Kaiser HE
    Anticancer Res; 1997; 17(2B):1319-30. PubMed ID: 9137492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical c-erbB-2 protooncogene expression and nuclear DNA content in human mammary carcinoma in situ.
    Schimmelpenning H; Eriksson ET; Pallis L; Skoog L; Cedermark B; Auer GU
    Am J Clin Pathol; 1992 May; 97(5 Suppl 1):S48-52. PubMed ID: 1374218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical evaluation of c-erbB-2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast.
    Lodato RF; Maguire HC; Greene MI; Weiner DB; LiVolsi VA
    Mod Pathol; 1990 Jul; 3(4):449-54. PubMed ID: 2170971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, P53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation.
    Ioachim E; Kamina S; Demou A; Kontostolis M; Lolis D; Agnantis NJ
    Anticancer Res; 1999; 19(3A):2133-9. PubMed ID: 10470161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer.
    Barbareschi M; Leonardi E; Mauri FA; Serio G; Dalla Palma P
    Am J Clin Pathol; 1992 Oct; 98(4):408-18. PubMed ID: 1357956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer.
    McCann AH; Dervan PA; O'Regan M; Codd MB; Gullick WJ; Tobin BM; Carney DN
    Cancer Res; 1991 Jun; 51(12):3296-303. PubMed ID: 1674898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroendocrine differentiation in colorectal carcinomas.
    Syversen U; Halvorsen T; Mårvik R; Waldum HL
    Eur J Gastroenterol Hepatol; 1995 Jul; 7(7):667-74. PubMed ID: 8590163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical expression of Bcl-2 protein in breast lesions: correlation with Bax, p53, Rb, C-erbB-2, EGFR and proliferation indices.
    Ioachim EE; Malamou-Mitsi V; Kamina SA; Goussia AC; Agnantis NJ
    Anticancer Res; 2000; 20(6B):4221-5. PubMed ID: 11205251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuron-specific enolase expression and neuroendocrine differentiation in carcinomas of the breast.
    Wilander E; Påhlman S; Sällström J; Lindgren A
    Arch Pathol Lab Med; 1987 Sep; 111(9):830-2. PubMed ID: 3632300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Spindle cell carcinoma of breast with neuroendocrine differentiation].
    Ding HY; Gao LX
    Zhonghua Bing Li Xue Za Zhi; 2006 Jan; 35(1):13-7. PubMed ID: 16608642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological characteristics of breast carcinomas with neuroendocrine cell differentiation.
    Yao GY; Zhou JL; Zhao ZS; Ruan J
    Chin Med J (Engl); 2004 Oct; 117(10):1536-40. PubMed ID: 15498379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.